ANRS 12300 Reflate TB2: RAL + 3TC/TDF Does Not Achieve Noninferior Efficacy vs EFV + 3TC/TDF at Wk 48 in ART-Naive Adults With HIV and TB

July 21-24, 2019; Mexico City, Mexico
First-line raltegravir 400 mg BID achieved HIV-1 RNA < 50 copies/mL in 61% of patients vs 66% with efavirenz 600 mg QD, each combined with 3TC/TDF in HIV/TB-coinfected patients receiving rifampin.
Format: Microsoft PowerPoint (.ppt)
File Size: 265 KB
Released: July 23, 2019

Acknowledgements

Provided by USF

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
IAS 2019 Media Partner Logo
Educational grant provided by:
Gilead Sciences
ViiV Healthcare

Related Content

Dr Christine Katlama discusses minimizing ART exposure with dual-therapy and intermittent dosing strategies, from Clinical Care Options (CCO)

person default Christine Katlama, MD Released: January 4, 2023

Dr Melissa Badowski shares key data about the causes of and recommendations for managing ART failure, from Clinical Care Options (CCO)

Melissa Badowski, PharmD, MPH, FIDSA, FCCP, BCIDP, BCPS, AAHIVP Physicians: maximum of 0.5 AMA PRA Category 1 Credits Pharmacists: 0.5 contact hours (0.05 CEUs) Released: December 23, 2022 Expired: December 22, 2023

Expert HIV faculty analyze new data from AIDS 2022, from Clinical Care Options (CCO)

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, AGPCNP-BC, ACRN, FAANP, FAAN, AAHIVS
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Princy N. Kumar, MD, FIDSA, MACP person default Mary W. Montgomery, MD David A. Wohl, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Registered Nurses: 1.5 Nursing contact hours Pharmacists: 1.5 contact hours (0.15 CEUs) Released: December 23, 2022 Expired: December 22, 2023

Dr Babafemi Taiwo discusses the emergence of lenacapavir for the treatment of multidrug-resistant HIV, from Clinical Care Options (CCO)

Babafemi Taiwo, MBBS Released: December 19, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings